Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Investors & Media
  • Contact
    Top Links
    • Investors & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Scientific Publications
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 – AML
      • Tipifarnib Clinical Trials
      • AIM-HN – HNSCC
      • KURRENT-HN – HNSCC
      • KURRENT-LUNG
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Investors & Media
    • Contact
    • MenuMenu

    Press Release

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    10-23-2019
    PDF Version

    – Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th –

    – Previously announced poster presentation rescheduled to take place following oral presentation –

    – Data embargoed until 11:50 a.m. ET on Tuesday, October 29th –

    SAN DIEGO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract containing data from the Company’s Phase 2 clinical trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) has been selected for oral presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 26-30, 2019 at the Hynes Convention Center in Boston.

    Nearly 500 abstracts were considered for this year’s program and just 10 were selected as short-talks by the Scientific Committee Cochairs. As a result of the selection, the previously announced poster presentation related to the Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC has been rescheduled to take place following the oral presentation. Details of the oral and poster presentations, entitled “Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations” (abstract A087), are as follows:

    Oral Presentation
    Session Title: Spotlight on Proffered Papers 3: Targeting RAS Mutant Cancers
    Session Date: Tuesday, October 29, 2019
    Session Start Time: 11:50 a.m. ET
    Session End Time: 12:30 p.m. ET
    Location: Level 3 - Ballroom AB

    Poster Presentation
    Session Title: Poster Session C: Clinical Trials 2
    Session Date: Tuesday, October 29, 2019
    Session Start Time: 12:30 p.m. ET
    Session End Time: 4:00 p.m. ET
    Location: Level 2 - Hall D

    The data are embargoed until the beginning of the Spotlight on Proffered Papers 3: Targeting RAS Mutant Cancers session at 11:50 a.m. ET on Tuesday, October 29, 2019. A copy of the oral and poster presentations will be available at www.kuraoncology.com following presentation at the meeting.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company is conducting a registration-directed trial in recurrent or metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura’s pipeline also includes KO-947, an ERK inhibitor, and KO-539, a menin-MLL inhibitor, both of which are currently in Phase 1 dose-escalation trials. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

    Contacts

    Company:
    Pete De Spain
    Vice President, Investor Relations &
    Corporate Communications
    (858) 500-8803
    pete@kuraoncology.com

    Investors:
    Robert H. Uhl
    Managing Director
    Westwicke Partners, LLC
    (858) 356-5932
    robert.uhl@westwicke.com

    Media:
    Jason Spark
    Managing Director
    Canale Communications
    (619) 849-6005
    jason@canalecomm.com

    Kura Oncology Logo

    Source: Kura Oncology, Inc.

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
    Footer Links - Investors
    • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top